𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

✍ Scribed by Rudin, C. M.; Hann, C. L.; Garon, E. B.; Ribeiro de Oliveira, M.; Bonomi, P. D.; Camidge, D. R.; Chu, Q.; Giaccone, G.; Khaira, D.; Ramalingam, S. S.; Ranson, M. R.; Dive, C.; McKeegan, E. M.; Chyla, B. J.; Dowell, B. L.; Chakravartty, A.; Nolan, C. E.; Rudersdorf, N.; Busman, T. A.; Mabry, M. H.; Krivoshik, A. P.; Humerickhouse, R. A.; Shapiro, G. I.; Gandhi, L.

Book ID
111981144
Publisher
American Association for Cancer Research
Year
2012
Tongue
English
Weight
314 KB
Volume
18
Category
Article
ISSN
1078-0432

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I Study of Navitoclax (ABT-263), a
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
✍ Gandhi, L.; Camidge, D. R.; Ribeiro de Oliveira, M.; Bonomi, P.; Gandara, D.; Kh πŸ“‚ Article πŸ“… 2011 πŸ› American Society of Clinical Oncology 🌐 English βš– 299 KB

## Purpose Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conduct